Display options
Cite
Perner A, Ibsen M, Bonde J. Attitudes to drug trials among relatives of unconscious intensive care patients. BMC Anesthesiol. 2010;10:6doi: 10.1186/1471-2253-10-6.
Perner, A., Ibsen, M., & Bonde, J. (2010). Attitudes to drug trials among relatives of unconscious intensive care patients. BMC anesthesiology, 106. https://doi.org/10.1186/1471-2253-10-6
Perner, Anders, et al. "Attitudes to drug trials among relatives of unconscious intensive care patients." BMC anesthesiology vol. 10 (2010): 6. doi: https://doi.org/10.1186/1471-2253-10-6
Perner A, Ibsen M, Bonde J. Attitudes to drug trials among relatives of unconscious intensive care patients. BMC Anesthesiol. 2010 May 26;10:6. doi: 10.1186/1471-2253-10-6. PMID: 20504325; PMCID: PMC2890661.
Copy Download .nbib Format: NLM
Share it on

BMC Anesthesiol. 2010 May 26;10:6. doi: 10.1186/1471-2253-10-6.

Attitudes to drug trials among relatives of unconscious intensive care patients.

BMC anesthesiology

Anders Perner, Michael Ibsen, Jan Bonde

Affiliations

  1. Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, Denmark. [email protected].

PMID: 20504325 PMCID: PMC2890661 DOI: 10.1186/1471-2253-10-6

Abstract

BACKGROUND: In many countries relatives are asked to consent on behalf of ICU patients prior to inclusion in clinical trials. However, the attitudes to drug trials among relatives of unconscious ICU patients are largely unknown.

METHODS: We performed a prospective questionnaire survey at two university hospital ICUs of the next-of-kin to 50 unconscious adult patients. They were asked to complete a questionnaire within 48 hours of the patients' acute ICU admission.

RESULTS: Forty-two relatives returned the questionnaire of which 41 were completed by direct family members and in one case by a friend to the patient.The majority of relatives (36/42) were positive/positive with some scepticism towards performing drug trials in unconscious ICU patients and 30/42 would most likely accept trial-participation by their relative. The majority (30/42) agreed that they should decide if their relative was to participate in a drug trial and 24 of these found that the treating clinician/ICU consultant should also consent. The majority (27/42) found that deferred consent would be acceptable if there was a limited time frame for initiation of treatment, however 8 respondents found this unacceptable when the intervention was a new drug.The majority of relatives stipulated that adherence to legislation, treatment benefit for the study patient and for future patients, no patient-risk or -discomfort and development of new drugs were important factors if their relative was to participate in an ICU drug trial. When questioned about doctors' motives for performing drug trials the wish for drug development and better patient care were highly rated among relatives.

CONCLUSIONS: In general, relatives to unconscious ICU patients expressed positive attitudes to drug trials in the ICU and the inclusion of their relative in drug trials. Consent by next-of-kin and deferred consent was acceptable to the majority of relatives.

References

  1. J Med Ethics. 2009 Nov;35(11):709-12 - PubMed
  2. Intensive Care Med. 2004 Feb;30(2):321-324 - PubMed
  3. Intensive Care Med. 2006 Dec;32(12):2020-5 - PubMed
  4. J Intern Med. 2002 Feb;251(2):156-68 - PubMed
  5. N Engl J Med. 2008 Feb 28;358(9):877-87 - PubMed
  6. Intensive Care Med. 1996 Jul;22(7):707-10 - PubMed
  7. Crit Care Med. 2009 Jan;37(1 Suppl):S65-8 - PubMed
  8. Intensive Care Med. 2009 Oct;35(10):1703-12 - PubMed
  9. Intensive Care Med. 2005 Mar;31(3):476-9 - PubMed
  10. Crit Care Med. 2004 Sep;32(9):1832-8 - PubMed
  11. Arch Dis Child Fetal Neonatal Ed. 2003 Jul;88(4):F280-5; discussion F285-6 - PubMed
  12. Curr Opin Crit Care. 2008 Dec;14(6):696-9 - PubMed
  13. Intensive Care Med. 2007 May;33(5):807-813 - PubMed
  14. N Engl J Med. 1999 Feb 11;340(6):409-17 - PubMed

Publication Types